Qi I Zeng

US Patent:

20120122837, May 17, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/242426

Inventors:

CLIFFORD CHENG - CAMBRIDGE MA, US
XIAOHUA HUANG - BROOKLINE MA, US
YING HUANG - BERKELEY HEIGHTS NJ, US
NING SHAO - WATCHUNG NJ, US
ASHWIN RAO - MORGANVILLE NJ, US
ANANDAN PALANI - BRIDGEWATER NJ, US
PETER ORTH - NEW YORK NY, US
JOHANNES H. VOIGT - CRANFORD NJ, US
ROBERT J. HERR - VOORHEESVILLE NY, US
LANA MICHELE ROSSITER - CLIFTON PARK NY, US
QI ZENG - DELMAR NY, US
XIANFENG SUN - GUILDERLAND NY, US

International Classification:

A61K 31/498
A61K 31/5377
A61K 31/4709
C07D 413/06
A61K 31/506
C07D 471/04
C07D 403/06
C07D 401/14
A61K 31/4985
C07D 403/14
C07D 241/44
A61P 3/04
A61P 3/10
A61P 9/10
A61P 3/06
A61K 31/55

US Classification:

51421018, 51421705, 5142348, 514249, 514312, 540599, 544116, 544295, 544350, 544354, 546157

Abstract:

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.